The prognostic role of serum uric acid level in patients with acute ST elevation myocardial infarction  by Omidvar, Bita et al.
P.O. Box 2925 Riyadh – 11461KSA
Tel: +966 1 2520088 ext 40151
Fax: +966 1 2520718
Email: sha@sha.org.sa
URL: www.sha.org.sa
O
R
IG
IN
A
L 
A
RT
IC
LE
Received 1 September 2011; revised 6 January 2012; accepted 23 January
2012.
Available online 1 February 2012
⇑ Corresponding author. Address: Department of Cardiology, Imam
Khomeini Hospital, Azadegan Avenue, Ahvaz Jundishapur University
of Medical Sciences, Ahvaz 6193673166, Iran. Tel./fax: +98 6114457205.
E-mail address: alastip@gmail.com (M. Alasti).The prognostic role of serum uric acid level
in patients with acute ST elevation myocardial
infarctionBita Omidvar a, Fazlolah Ayatollahi a, Mohammad Alasti b,⇑aDepartment of Internal Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz; bDepartment
of Cardiology, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
a,b IranObjectives: The role of uric acid as a prognostic factor in patients with acute ST elevation myocardial infarction is
controversial. The purpose of this study was to demonstrate the relationship between serum uric acid level and
mortality during admission period and 30-day period after admission.
Methods: We assessed the relation between serum uric acid level and in-hospital and short-term mortality rates in
184 patients admitted with acute ST elevation myocardial infarction. We divided the patients according to their gen-
der and uric acid level measured on admission into four groups: group A1: men with uric acid 67 mg/dl versus group
B1: men with uric acid >7 mg/dl and group A2: women with uric acid 65.6 mg/dl versus group B2: women with uric
acid >5.6 mg/dl. The patients were followed for 30 days after admission.
Results: In-hospital mortality rate in group B1 was higher than group A1 [P value: 0.011, Relative risk: 13.33 (95%
confidence interval: 1.55–114.7)]. Short-term all-cause mortality was significantly higher in group B1 patients [P
value: 0.037, Relative risk: 3.3 (95% confidence interval: 1.02–10.64)]. Multivariate logistic regression analysis of data
showed an odds ratio of 15.23 for in-hospital mortality and odds ratio of 3.76 for short-term mortality in male hyper-
uricemic patients.
Conclusions: Our data suggest that in the acute phase of ST elevation myocardial infarction, uric acid has a prog-
nostic role for in-hospital and short-term (30-day) mortality in men.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
Keywords: Uric acid, ST elevation myocardial infarction, Prognosis, MortalityAcute myocardial infarction is one of the mostpredominant causes of mortality worldwide.
There are some markers indicating unfavorable
prognosis in patients with acute myocardial
infarction. Uric acid is one of the markers that1016–7315  2012 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
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doi:10.1016/j.jsha.2012.01.005has been evaluated in research. The role of uric
acid as a risk factor for cardiovascular disease or
a prognostic factor is controversial. Uric acid is
produced by the enzymatic activity of xanthine
oxidase and is the final product of purine metabo-
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this process that may have a role in cardiovascular
disease. Some studies suggested that uric acid can
cause intracellular stress and inflammation lead-
ing to endothelial injury and enhancement of
vasoconstrictor effects [2].
According to much research, uric acid could be a
marker of adverse prognosis in patients with acute
myocardial infarction but there are studies that
showed no relation between serum uric acid level
and mortality rate. On the other hand, these stud-
ies differ in type of perfusion and number size [2–
8]. Therefore, we designed an observational cohort
study aimed at evaluating the relation between
serum uric acid level and short-term mortality in
patients with acute ST elevation myocardial
infarction (STEMI).Methods
The patients included in the study were selected
consecutively among those admitted with acute
STEMI on the basis of the following inclusion cri-
teria: (1) resting chest pain lasting more than
30 min; (2) typical ischemic ST elevation in electro-
cardiogram (ECG) leads; and (3) rise of serum car-
diac enzymes concentration (CK-MB and
Troponins). We excluded patients who: (1) did
not receive thrombolytic therapy during the first
six hours after the onset of chest pain; (2) were
in cardiogenic shock (3) had previous pacemaker
implantation; (4) had a recent myocardial infarc-
tion (<3 months); (5) had severe valvular disease;
(6) had impaired renal function (serum creatinine
level >1.5 mg/dl); (7) had known cases of hypothy-
roidism, malignancy, gout or other inflammatory
diseases and were using corticosteroid or cytotoxic
drugs.
All patients underwent a standard 12-lead ECG
and echocardiographic examination. ECGs were
recorded at a speed of 25 mm/s and a scale of
10 mm/mV.
Patients were imaged in the left lateral decubitus
position in the parasternal and apical views using a
commercially available system (Vingmed Seven,
General Electric-Vingmed, Milwaukee, WI, USA)
during the first day of admission. Left ventricular
ejection fraction (LVEF) was calculated from
the conventional apical two- and four-chamber
images, using the biplane Simpson’s technique.
Blood samples were obtained immediately after
admission. Uric acid and other biochemical param-
eters were measured. We used Parsazmun photo-
metric kits to measure uric acid. Serum creatinine
anduric acid concentrationswere expressed asmil-ligrams per deciliter (mg/dl). Serum creatine ki-
nase and creatine kinase-MB were measured and
expressed as international units per liter (IU/L)
and micrograms per liter (lg/L). Body weight and
height were measured during admission and Body
Mass Index (BMI) was calculated.
Hypertension was defined as taking antihyper-
tensive drugs or baseline blood pressure equals
to 140/90 mmHg or more. Diabetes Mellitus
(DM) was defined as taking hypoglycemic agents
or fasting plasma glucose level at or above
126 mg/dl, a two-hour value in an oral glucose tol-
erance test at or above 200 mg/dl, or a random
plasma glucose concentration P200 mg/dl in the
presence of symptoms. Hyperlipidemia was de-
fined as a total cholesterol level P220 mg/dl or a
triglyceride level P150 mg/dl. Active smoking
was defined as risk factor.
Normal levels of uric acid were defined 2.5–
5.6 mg/dl in women and 3.1–7 mg/dl in men
according to our reference laboratory.
The patients underwent selective coronary angi-
ography and revascularization according to cur-
rent guidelines [9].
We divided the patients into four groups accord-
ing to their serum uric acid level and gender.
Group A1 consisted of male patients with serum
uric acid level of 7 mg/dl or less and group B1 con-
sisted of male patients with serum uric acid level
more than 7 mg/dl. Group A2 consisted of female
patients with serum uric acid level of 5.6 mg/dl
or less and group B2 consisted of female patients
with serum uric acid level more than 5.6 mg/dl.
ASA, beta blockers, angiotensin converting en-
zyme inhibitors or angiotensin II receptor blockers
and statins were prescribed for all of the patients
during admission and after discharge. We fol-
lowed the patients for 30 days after admission.
The primary aims of the study were comparing
mortality from any cause during the 30-day period
after STEMI and the in-hospital mortality rate be-
tween groups.
The study protocol was approved by ethics com-
mittee of Jundishapur University of Medical Sci-
ences. All patients provided written informed
consent.
Continuous data were expressed as mean ±
standard deviation values.
Fisher’s exact test and Chi-square test and stu-
dent t-test were used to compare groups. For cor-
rection of potential confounding factors on in-
hospital mortality and short-term mortality, we
used backward elimination multivariate logistic.
A P-value less than 0.05 was considered to be sta-
tistically significant.
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The study population consisted of 184 patients
[129 men (70.1%) and 55 women (29.9%)].The
mean age was 58 ± 11.7 years (range: 26–80 year)
and the mean body mass index (BMI) was
26.54 ± 1.31 (23–32.1).
Sixty-eight (37%) patients had hypertension.
History of DM, hyperlipidemia and smoking were
present in fifty-four (29.3%), sixty-one (33.2%) and
eighty-give (46.2%) cases, consecutively.
Fifty-five patients (29.9%) had a history of coro-
nary artery disease. Eight patients (4.3%) had his-
tory of coronary artery bypass graft (CABG)
surgery and seventeen cases (9.2%) had history
of percutaneous coronary intervention (PCI).
Ninety-four patients (51.1%) had anterior myocar-
dial infarction and ninety patients (48.9%) had
inferior myocardial infarction. The time from
chest pain onset was 2.91 ± 0.48 h (range: 1.5–
4 h).One hundred and fifty-four patients (83.7%)
were in Killip’s class I and the remainder were
in Killip’s class II. The mean of serum creatinine
level was 1.06 ± 0.24 mg/dl (range: 0.5–1.5 mg/dl)
and the mean of serum uric acid level was
5.74 ± 1.91 mg/dl (range: 2–12 mg/dl).
Mean LVEF was 41.2 ± 9.3% (range: 10–60%).
The duration of hospitalization was 7.3 ± 3.5 day
(range: 2–30 day).Table 1. Baseline characteristics of patients in group A1 (UA 6 7 m
Variable Group A1 (N = 9
Age (years) 55.7 ± 10.76
BMI (kg/m2) 27.5 ± 0.52
Hypertension, n 25
Diabetes Mellitus, n 28
Dyslipidemia, n 19
Smoking, n 63
History of CAD, n 27
History of CABG, n 4
History of PCI, n 8
Creatinine (mg/dl) 1.07 ± 0.21
Uric acid (mg/dl) 5.04 ± 1.24
Time from chest pain onset (h) 2.78 ± 0.52
Location of MI, n
Anterior 45
Inferior 50
Creatine kinase (IU/L) 2240.44 ± 618.99
Creatine kinase-MB mass (lg/L) 219.6 ± 62.2
Killip’s class, n
I 83
II 16
LVEF (%) 42.62 ± 8.71%
Hospitalization duration (day) 6.62 ± 8.71
In-hospital death 1
Short-term mortality 5
* Statistically significant difference between two groups (P < 0.05).Patients’ baseline characteristics in group A1
versus group B2 and group A2 versus group B2
are presented in Tables 1 and 2.
There was no significant difference between the
patient’s baseline characteristics in group A1 ver-
sus group B1 except age and serum creatinine le-
vel. We did not find any significant difference
between patient’s baseline characteristics in
group A2 versus group B2.
Cardiac events were the cause of mortality in all
our patients.
The in-hospital mortality rate in group B1 was
higher than group A1 [P value: 0.011, Relative risk:
13.33 (95% confidence interval: 1.55–114.7)]. Short-
term (30-day) all-cause mortality was significantly
higher in group B1 patients [P value: 0.037, Rela-
tive risk: 3.3 (95% confidence interval: 1.02–10.64)].
In female patients (group A2 versus group B2),
we did not find any significant relation between
serum uric acid level and in-hospital and short-
term mortality.
After adjusting for age, hypertension, DM, dysli-
pidemia, smoking, BMI, ejection fraction and
serum creatinine level, multivariate logistic regres-
sion analysis of data showed a significant differ-
ence between group A1 and group B1 and uric
acid was confirmed as an independent predictor
for in-hospitalmortality [odds ratio: 15.23 (95%con-
fidence interval: 1.39–117.3)] and short termmortal-g/dl) and patients in group B1 (UA > 7 mg/dl).
9) Group B1 (N = 30) P value
61.97 ± 12.99* 0.012
2.86 ± 0.39 0.831
12 0.122
8 0.882
17 0.862
14 0.101
10 0.521
1 0.611
3 0.432
1.19 ± 0.22* 0.012
8.42 ± 1.38* 0.000
2.82 ± 0.49 0.432
0.437
18
16
2239.23 ± 635.95 0.901
229 ± 64.59 0.473
0.213
26
4
40.34 ± 10.63% 0.244
7.43 ± 2.89 0.212
4* 0.011
5* 0.037
Table 2. Baseline characteristics of patients in group A2 (UA 6 5.6 mg/dl) and patients in group B2 (UA > 5.6 mg/dl).
Variable Group A2 (N = 28) Group B2 (N = 27) P value
Age (years) 59.25 ± 11.39 60.33 ± 12.31 0.732
BMI (kg/m2) 26.76 ± 1.49 26.29 ± 0.94 0.464
Hypertension, n 15 16 0.673
Diabetes Mellitus, n 14 13 0.891
Hyperlipidemia, n 13 12 0.883
Smoking, n 6 2 0.144
History of CAD, n 6 12 0.081
History of CABG, n 1 2 0.342
History of PCI, n 2 4 0.187
Creatinine (mg/dl) 0.93 ± 0.22 1.01 ± 0.28 0.114
Uric acid (mg/dl) 3.95 ± 0.81 7.18 ± 1.25* 0.000
Time from chest pain onset (h) 3.03 ± 0.48 3 ± 0.52 0.791
Location of MI, n 0.753
Anterior 16 15
Inferior 12 12
Creatine kinase (IU/L) 2161.57 ± 608.65 2193.56 ± 519.27 0.832
Creatine kinase-MB mass (lg/L) 214.25 ± 65.12 25.07 ± 59.91 0.523
Killip’s class 0.115
I 24 21
II 4 6
LVEF (%) 40.41 ± 7.63% 37.62 ± 10.67% 0.112
Hospitalization duration (day) 8.21 ± 2.42 8.96 ± 4.96 0.471
In-hospital death 0 1 0.491
Short-term mortality 0 2 0.147
* Statistically significant difference between two groups (P < 0.05).
Table 3. Effects of variables on in-hospital mortality in unadjusted and adjusted multivariate logistic regression analysis.
Variable Unadjusted odds
ratio
95% Confidence
interval
P
value
Adjusted odds
ratio
95% Confidence
interval
P
value
Age 1.317 1.076–1.612 0.007* 1.089 0.804–1.763 0.750
Hypertension 1.257 0.220–7.177 0.797 0.00 0 0.975
Diabetes
mellitus
4.125 0.783–21.722 0.095 0.45 0–59.765 0.137
Dyslipidemia 5.687 0.944–32.55 0.067 3.68 0–8.987 0.862
Smoking 0.000 0 0.997 0.000 0 0.997
LVEF 0.897 0.826–1.055 0.065 0.000 0 0.975
Creatinine 33.567 0.437–257.71 0.113 2.510 0–765.564 0.616
Uric acid 14.768 1.294–48.011 0.025* 15.23 1.39–117.3 0.037*
* Statistically significant difference between two groups (P < 0.05).
Table 4. Effects of variables on short-term mortality in unadjusted and adjusted multivariate logistic regression analysis.
Variable Unadjusted odds
ratio
95% Confidence
interval
P
value
Adjusted odds
ratio
95% Confidence
interval
P
value
Age 1.160 1.055–1.279 0.021* 1.154 0.945–1.275 0.058
Hypertension 0.826 0.191–3.567 0.799 0.354 0.047–2.633 0.310
Diabetes
Mellitus
2.783 0.725–10.625 0.136 3.324 0.047–2.633 0.224
Dyslipidemia 2.834 0.772–11.529 0.113 4.124 0.862–18.50 0.074
Smoking 0.420 0.112–1.569 0.197 0.976 0.101–1.565 0.101
LVEF 0.942 0.883–1.005 0.081 0.985 0.910–1.065 0.701
Creatinine 8.185 3.382–198.401 0.196 6.64 0.085–520.701 0.395
Uric acid 3.78 1.009–24.015 0.049* 3.76 1.020–17.530 0.011*
* Statistically significant difference between two groups (P < 0.05).
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17.53)]. The results of multivariate logistic regres-
sion analysis are presented in Tables 3 and 4.
Ninety-one patients underwent selective coro-
nary angiography that showed multi-vessel dis-
ease in fifty-four patients (59.3%) and significant
LAD lesion in seventy-six patients (83.5%). Seven-
teen of fifty-two patients in group A1 who under-
went coronary angiography had multi-vessel
disease while eight of the sixteen group B1 pa-
tients had multi-vessel disease. Ten of the
twenty-seven patients in group A2 had multi-ves-
sel disease while nine of the fifteen group B2 pa-
tients who underwent coronary angiography had
multi-vessel disease. There was no statistically
significant difference between groups.
Thirty-nine patients in group A1 and twelve pa-
tients in group B1 had significant LAD lesions. Fif-
teen patients in group A2 had significant LAD
lesions while ten of the group B2 patients who
underwent coronary angiography had significant
LAD lesions. There was no significant difference
in LAD lesion prevalence between groups.
During follow up, four patients of group A1 and
two patients of group B1 underwent CABG and
nine patients of group A1 and six patients of group
B1 underwent PCI. One patient in group A2 and
one patient in group B2 underwent CABG. Three
patient of group A2 and three patients of group
B2 underwent PCI. Therefore, there was no signif-
icant difference between revascularization rates
between groups.
No device was implanted during follow up.Discussion
In the present study, we found a strong relation
between serum uric acid levels at the time of
admission and in-hospital and short-term mortal-
ity in male patients with STEMI. The all-cause
mortality rate of male patients with serum uric
acid concentrations of more than 7 mg/dl or more
was 3.76 times higher than those with uric acid
concentrations of 7 mg/dl or more during the first
month after admission.
The role of uric acid as a risk factor for myocar-
dial infarction is controversial. There are a lot of
studies suggesting that hyperuricemia is a risk
factor for cardiovascular disease [10,11]. The Fra-
mingham Heart study demonstrated that uric acid
was not a risk factor for cardiovascular events [11],
and therefore most medical societies have not
considered serum uric acid level as a cardiovascu-
lar risk factor [11].Whereas Homayounfar et al. [4] concluded that
uric acid was not an independent prognostic mar-
ker for in-hospital mortality after acute myocar-
dial infarction, there are many studies that have
showed uric acid could be a marker of adverse
prognosis in patients with acute myocardial
infarction [3,5–8]. Recently, Wasserman et al. doc-
umented that uric acid was an independent pre-
dictor of in-hospital mortality in medical patients
[1].
To clarify how uric acid plays a role as a prog-
nostic factor in STEMI, production of uric acid is
elevated in association with increased xanthine
oxidase activity. During uric acid production, oxy-
gen free radicals are generated and therefore, uric
acid may be a simple and useful clinical indicator
of excess oxidative stress [6,12]. The generation of
oxygen free radicals is one of probable mecha-
nisms involved in the no-reflow phenomenon
during reperfusion therapy. On the other hand,
hyperuricemia is associated with decreased pro-
duction of nitric oxide and endothelial dysfunc-
tion and myocardial microvascular disease and
local inflammation [2,6].
Hyperuricemia may also be related to impaired
uric acid excretion caused by low cardiac output
and tissue hypoxia. In some studies, serum uric
acid level correlated with severity of the Killip
classification [5,8]. In our patients, the creatinine
level in group B patients was higher than group
A but the Killip’s class and LVEF and other clinical
characteristics of both groups were not different.
So, the difference in cardiac output could not ex-
plain this in our patients.
We did not find any relation between hyperuri-
cemia and short-term mortality in female patients
with STEMI. The most possible explanation could
be the low number of our patients.
In conclusion, although there are other biomark-
ers correlating with increased mortality risk in pa-
tients with STEMI, our study supported that
serum uric acid could be another potential impor-
tant biomarker of short-term mortality.
Some limitations of our study also need to be
acknowledged. The major limitation of the present
study may be represented by the small number of
patients. Also, we did not compare the prevalence
of using drugs like thiazide diuretics or other
usual drugs than can change serum uric acid level
among our groups. Another limitation is that most
of our patients were male. A large study, espe-
cially with more female patients, could be more
informative. Another limitation of the study is that
we did not follow the exact adherence rate of our
patients to their prescribed drugs.
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Our data suggest that serum uric acid level has a
prognostic role in in-hospital and 30-day mortality
of male STEMI patients. This can be a useful bio-
marker for predicting short-term mortality in this
group of patients.Disclosures
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